Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer
NCT05226728
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer
Interventions
DRUG:
pembrolizumab
Sponsor
Sun Yat-sen University